Cardiovascular Diseases among Patients with Cancer and Patients living with HIV

项目摘要/摘要：Tomas Neilan医学硕士是临床活跃的心脏病专家 马萨诸塞州总医院的心脏病学和心血管影像学副教授 哈佛医学院的医学专业。在过去的10年里，Neilan博士的研究重点是应用 两个互补领域的先进成像，与癌症治疗相关的心血管毒性 以及艾滋病毒携带者中的心力衰竭。Neilan博士丰富的指导经验、出版和 资助记录，加上他目前和计划中的研究支持，表明了他的承诺和 对POR的热情，并为实现K24奖的目标和目的提供了良好的基础。 K24奖的具体目的是：1)使Neilan博士能够致力于25%的 他根据NIH已经资助的项目指导初级临床研究人员的时间；2)指导初级临床研究人员 T-32项目的临床研究人员和心脏病学住院医师、研究员和初级教员 和放射学，目标是将他们培养成能够成功竞争同行的临床研究人员 审查拨款；以及3)使Neilan博士能够整合POR，将创新的翻译、 心血管成像的临床和结果研究，并提供了一个理想的发展环境 未来临床研究的领导者。Neilan博士目前的领导角色与这一提议非常吻合。他就是那个 心血管成像临床研究项目--心脏MR CT PET项目的联合主任 在心脏科和放射科的支持下，该院副主任 T32心血管成像培训补助金，以及该司心脏肿瘤学项目主任 心脏病学博士。除了他的角色，Neilan博士还从领导层那里毫无保留地承诺 心脏病学和放射学都为成功指导初级临床提供了理想的基础 并达到调查人员获奖的目的。这项拨款的具体研究目标源于一项 过去几年完成的大量工作都是基于NIH正在资助的 项目，但目标4除外，它是由这笔赠款特别支持的新研究： 1)STOP-CA--一项随机多中心临床试验中他汀类药物对左心功能减退的影响 2)安慰剂化疗后的心室射血分数： 他汀类药物是否能减轻心肌纤维化、心肌脂肪变性和心肌梗死 在艾滋病毒携带者中保护心脏功能，3)Stop-CA Fibrosis-我们应用新的MRI- 以成像技术为基础，深入了解心肌纤维化在心脏疾病发展中的作用 并检测他汀类药物对蒽环类药物心肌纤维化的影响。 和4)扩大我们的国际注册，以改善我们对预测因素、陈述、 免疫检查点抑制剂(ICI‘s)后心肌炎患者的治疗和结果。

Project Summary/Abstract: Tomas Neilan MD MPH is a clinically-active cardiologist in the Division of Cardiology and Cardiovascular Imaging at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Over the last 10 years, Dr. Neilan’s research has focused on applying advanced imaging to two complementary areas, the cardiovascular toxicities associated with cancer therapies and heart failure among persons with HIV. Dr. Neilan’s extensive mentoring experience, publication and funding record, together with his current and planned research support, demonstrate his commitment and passion for POR and provide an excellent foundation to accomplish the goals and objectives of the K24 Award. The specific aims addressing the purpose of the K24 Award are: 1) To enable Dr. Neilan to dedicate 25% of his time to mentor junior clinical investigators based on already NIH funded projects; 2) To mentor junior clinical investigators from the T-32 program and the pool of residents, fellows, and junior faculty in Cardiology and Radiology with the goal to develop them into clinical researchers who can successfully compete for peer reviewed grants; and 3) To enable Dr. Neilan to consolidate a POR that combines innovative translational, clinical, and outcomes research in cardiovascular imaging and that provides an ideal environment to develop future leaders in clinical research. Dr. Neilan’s current leadership roles align well with this proposal. He is the Co-Director of the Cardiac MR CT PET Program, a clinical research program in cardiovascular imaging supported by the Division of Cardiology and the Department of Radiology, the Associate Director of the MGH T32 training grant in cardiovascular imaging, and the Director of the Cardio-Oncology Program in the Division of Cardiology. In addition to his roles, Dr. Neilan also has an unreserved commitment from the leadership of both Cardiology and Radiology providing a foundation that is ideal to successfully mentor junior clinical investigators and fulfill the purpose of the Award. The specific research aims of this grant stem from a significant body of work accomplished over the past few years and are all based on on-going NIH funded projects, except Aim 4 which is new research specifically supported by this grant: 1) STOP-CA – Testing in a randomized multicenter clinical trial the effect of statins on the reduction in left ventricular ejection fraction after anthracycline-based chemotherapy, 2) REPRIEVE-MR – Testing in a randomized multicenter clinical trial whether statins reduce myocardial fibrosis, myocardial steatosis and preserve cardiac function among persons living with HIV, 3) STOP-CA Fibrosis – where we apply novel MRI- based imaging techniques to provide insight into the role of myocardial fibrosis in the development of anthracycline-induced cardiotoxicity, and test the effect of statins on myocardial fibrosis after anthracyclines, and 4) Expanding our international registry to improve our limited understanding of the predictors, presentation, treatments and outcomes of patients presenting with myocarditis after immune checkpoint inhibitors (ICI’s).